State of the art - how I manage coagulopathy in cardiac surgery patients.

摘要: Over 35 000 cardiac operations using cardiopulmonary bypass are performed annually in the UK. Post-operative bleeding is a common cause of morbidity. Although there have been improvements surgical techniques, recent publications still show post-operative blood loss to be significant, with allogeneic product usage as high 50%. Despite greater understanding mechanisms coagulopathy encountered during surgery development treatment options has slow. There realization inadequacy fresh frozen plasma correct this setting, leading off-label use specific factor concentrates stop bleeding, e.g., prothrombin complex and fibrinogen concentrates. Recent trials XIII IX not successful. This article will review preventative measures reduce current management such and, most cases, limited evidence supporting their widespread use.